Clinical Trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Study acronym: VECTRA-01
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Protocol Amendment History 1 change
notable Trial sites expanded: 90 -> 104 locations 2026-07-02
Trial Details
NCT Number NCT07611110
Lead Sponsor AstraZeneca
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 670 participants
Start Date 2026-05-04
Primary Completion 2029-02-13 (estimated)
Study Completion 2029-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-01